Market boundary:
Credence Research defines this market as regulated or regulation-bound medical software in which generative AI, foundation models, multimodal models or large language models contribute directly to diagnostic interpretation, clinical decision support, image or signal processing, triage, treatment planning or another medical-device function. General-purpose hospital copilots, administrative AI, non-device wellness applications and pharmaceutical discovery software are excluded.
The FDA does not publish a separate revenue category for generative AI SaMD. Its AI-enabled medical device list covers AI devices broadly and the agency has stated that it intends to improve identification of devices incorporating foundation models and LLM-based functionality. Market values, volumes, vendor shares, CR4 and HHI figures below are therefore Credence Research econometric estimates built from regulatory records, commercial deployment indicators, vendor disclosures and normalized software pricing.
| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2021-2024 |
| Base Year |
2025 |
| Forecast Period |
2026-2035 |
| Generative AI in Software as a Medical Device (SaMD) Market Size 2025 |
USD 1.4 billion |
| Generative AI in Software as a Medical Device (SaMD) Market, CAGR |
24.52% |
| Generative AI in Software as a Medical Device (SaMD) Market Size 2032 |
USD 14.2 billion |
Executive market sizing summary and macro scenario outlook
The global Generative AI in Software as a Medical Device market was valued at an estimated USD 1.4 billion in 2025, representing approximately 158,000 active regulated license-equivalents. Revenue is projected to reach USD 14.2 billion by 2035, while deployed license-equivalents rise to 1.416 million. This implies a 26.50% value CAGR and 24.52% volume CAGR from 2026 to 2035. Normalized annual ASP increases from USD 8,354 to USD 9,781, primarily because multimodal clinical systems gain mix share.
FDA policy provides a clearer mechanism for controlled AI updates through Predetermined Change Control Plans. The final guidance permits sponsors to define planned modifications, validation methods and impact assessments within an approved framework. In Europe, current AI Act implementation places high-risk obligations for AI systems tied to regulated products on a later compliance schedule, with the current amended timetable extending relevant Annex I high-risk requirements to Aug. 2, 2028.
Macro Scenario Forecast Modeling
| Scenario |
2025 Value |
2035 Forecast Value |
10-Year CAGR |
Primary Macro / Regulatory Assumptions |
| Bull case |
USD 1.4 Bn |
USD 16.20 Bn |
28.50% |
Faster foundation-model clearances, broader PCCP use, shortened hospital validation cycles, favorable reimbursement and faster APAC clinical AI procurement |
| Base case |
USD 1.4 Bn |
USD 14.2 Bn |
26.50% |
Controlled regulatory expansion, continued radiology adoption, progressive multimodal validation and sustained cloud deployment |
| Bear case |
USD 1.4 Bn |
USD 11.81 Bn |
24.50% |
Longer prospective validation requirements, liability concerns, hospital IT integration delays and higher compliance costs |
Key Market Indicators
| Market Indicator |
2025 / Base Metric |
2035 / Forecast Metric |
| Market value |
USD 1.4 Bn |
USD 14.2 Bn |
| Revenue CAGR |
26.50% |
2026-2035 |
| Installed-base CAGR |
24.52% |
2026-2035 |
| Active regulated license-equivalents |
158,000 |
1,416,000 |
| Normalized annual ASP |
USD 8,354 |
USD 9,781 |
| Largest regional share |
North America: 44.00% |
North America: 39.00% |
| CR4 concentration ratio |
34.80% |
Moderate consolidation expected |
| HHI concentration index |
Approximately 620 |
Fragmented market structure |
Volume definition: One license-equivalent represents one normalized annual revenue-bearing production deployment of a regulated or regulation-bound generative AI medical-device function. Enterprise platform contracts that contain multiple algorithms or sites are converted into equivalent annual production licenses for cross-vendor comparison.
Deep-Dive Segmentation and Sub-Segment Value-Volume Analysis
By Solution Type and Functional Architecture
| Segment / Sub-Segment |
2025 Value (USD Mn) |
2035 Value (USD Mn) |
Value CAGR |
2025 Volume (000 Licenses) |
2035 Volume (000 Licenses) |
Volume CAGR |
2025 ASP |
2035 ASP |
| Parent: Generative diagnostic and decision applications |
805.20 |
8,171.50 |
26.08% |
93.22 |
807.12 |
24.09% |
USD 8,638 |
USD 10,124 |
| Child: Report generation and structured findings |
316.80 |
2,770.00 |
24.21% |
42.66 |
311.52 |
22.00% |
USD 7,426 |
USD 8,892 |
| Child: Multimodal diagnostic decision support |
290.40 |
3,462.50 |
28.13% |
25.28 |
269.04 |
26.68% |
USD 11,487 |
USD 12,870 |
| Child: Risk synthesis and explainable recommendation support |
198.00 |
1,939.00 |
25.63% |
25.28 |
226.56 |
24.52% |
USD 7,832 |
USD 8,558 |
| Parent: Generative image and signal processing |
316.80 |
3,462.50 |
27.02% |
36.34 |
339.84 |
25.05% |
USD 8,718 |
USD 10,189 |
| Child: Reconstruction, denoising and image synthesis |
145.20 |
1,385.00 |
25.30% |
17.38 |
141.60 |
23.34% |
USD 8,354 |
USD 9,781 |
| Child: Foundation-model segmentation and contouring |
105.60 |
1,246.50 |
28.00% |
11.06 |
113.28 |
26.19% |
USD 9,548 |
USD 11,004 |
| Child: Synthetic clinical data generation |
66.00 |
831.00 |
28.83% |
7.90 |
84.96 |
26.81% |
USD 8,354 |
USD 9,781 |
| Parent: Regulated workflow and orchestration |
198.00 |
2,216.00 |
27.32% |
28.44 |
269.04 |
25.20% |
USD 6,962 |
USD 8,237 |
| Child: Clinical summarization and device documentation |
92.40 |
1,108.00 |
28.20% |
12.64 |
127.44 |
26.00% |
USD 7,310 |
USD 8,694 |
| Child: Triage and workflow orchestration |
66.00 |
692.50 |
26.50% |
9.48 |
84.96 |
24.52% |
USD 6,962 |
USD 8,151 |
| Child: Patient-facing regulated generative output |
39.60 |
415.50 |
26.50% |
6.32 |
56.64 |
24.52% |
USD 6,266 |
USD 7,336 |
Generative diagnostic and decision applications represented 61% of 2025 revenue but are modeled at 59% by 2035. The internal mix changes more substantially. Report generation declines from 24% to 20% of total market revenue, while multimodal diagnostic decision support increases from 22% to 25%. This shift reflects higher contract values for software that combines imaging, structured EHR data, laboratory results and clinical text.
Foundation-model segmentation and synthetic-data applications collectively increase from 13% of market revenue in 2025 to 15% by 2035. GE HealthCare has already demonstrated research foundation models for MRI and X-ray applications, including models designed for segmentation, classification and report-generation development. Its MRI research model has been trained on more than 200,000 MRI images in later development work. Aidoc provides stronger evidence of direct regulatory migration: its CARE foundation model now supports FDA-cleared clinical applications.
By Deployment Architecture
| Segment / Sub-Segment |
2025 Value (USD Mn) |
2035 Value (USD Mn) |
Value CAGR |
2025 Volume (000 Licenses) |
2035 Volume (000 Licenses) |
Volume CAGR |
2025 ASP |
2035 ASP |
| Parent: Cloud and SaaS deployment |
712.80 |
9,556.50 |
29.64% |
91.64 |
1,047.84 |
27.59% |
USD 7,778 |
USD 9,120 |
| Child: Public cloud multi-tenant SaaS |
382.80 |
5,540.00 |
30.63% |
52.14 |
623.04 |
28.15% |
USD 7,342 |
USD 8,892 |
| Child: Private cloud and virtual private cloud |
198.00 |
2,631.50 |
29.53% |
22.12 |
254.88 |
27.69% |
USD 8,951 |
USD 10,324 |
| Child: Hybrid cloud deployment |
132.00 |
1,385.00 |
26.50% |
17.38 |
169.92 |
25.61% |
USD 7,595 |
USD 8,151 |
| Parent: On-premise and edge deployment |
607.20 |
4,293.50 |
21.60% |
66.36 |
368.16 |
18.69% |
USD 9,150 |
USD 11,662 |
| Child: On-premise clinical server |
330.00 |
2,216.00 |
20.98% |
36.34 |
184.08 |
17.61% |
USD 9,081 |
USD 12,038 |
| Child: Edge and embedded device deployment |
277.20 |
2,077.50 |
22.31% |
30.02 |
184.08 |
19.88% |
USD 9,234 |
USD 11,286 |
Cloud and SaaS deployment increases from 54% of revenue in 2025 to 69% in 2035. Public cloud configurations produce the strongest value CAGR at 30.63%. The pricing discount relative to private cloud expands adoption among smaller hospital systems, outpatient imaging networks and specialist providers.
Private-cloud ASP remains higher because contracts include dedicated infrastructure, security controls, model monitoring and institution-specific validation. Philips reported that more than 150 sites in North and Latin America had migrated to its AWS-hosted HealthSuite Imaging services before the company expanded the offering into Europe and began exploring generative AI for radiology reporting. GE HealthCare also selected AWS for development of purpose-built healthcare foundation models and generative AI applications.
By Clinical Specialty
| Segment / Sub-Segment |
2025 Value (USD Mn) |
2035 Value (USD Mn) |
Value CAGR |
2025 Volume (000 Licenses) |
2035 Volume (000 Licenses) |
Volume CAGR |
2025 ASP |
2035 ASP |
| Parent: Imaging-led diagnostics |
712.80 |
6,371.00 |
24.49% |
90.06 |
679.68 |
22.40% |
USD 7,915 |
USD 9,374 |
| Child: Radiology |
501.60 |
4,293.50 |
23.95% |
63.20 |
453.12 |
21.77% |
USD 7,937 |
USD 9,475 |
| Child: Digital pathology |
118.80 |
1,246.50 |
26.50% |
14.22 |
141.60 |
25.84% |
USD 8,354 |
USD 8,803 |
| Child: Women’s health imaging |
92.40 |
831.00 |
24.56% |
12.64 |
84.96 |
20.99% |
USD 7,310 |
USD 9,781 |
| Parent: Physiologic and specialty diagnostics |
330.00 |
3,739.50 |
27.48% |
37.92 |
368.16 |
25.52% |
USD 8,703 |
USD 10,157 |
| Child: Cardiology |
171.60 |
2,077.50 |
28.32% |
18.96 |
198.24 |
26.45% |
USD 9,051 |
USD 10,480 |
| Child: Neurology |
92.40 |
969.50 |
26.50% |
11.06 |
99.12 |
24.52% |
USD 8,354 |
USD 9,781 |
| Child: Respiratory and other specialty diagnostics |
66.00 |
692.50 |
26.50% |
7.90 |
70.80 |
24.52% |
USD 8,354 |
USD 9,781 |
| Parent: Multimodal treatment decision and monitoring |
277.20 |
3,739.50 |
29.72% |
30.02 |
368.16 |
28.49% |
USD 9,234 |
USD 10,157 |
| Child: Oncology |
132.00 |
1,939.00 |
30.83% |
12.64 |
169.92 |
29.67% |
USD 10,443 |
USD 11,411 |
| Child: Rare disease and genomics |
52.80 |
692.50 |
29.35% |
6.32 |
70.80 |
27.33% |
USD 8,354 |
USD 9,781 |
| Child: General medicine and multi-specialty |
92.40 |
1,108.00 |
28.20% |
11.06 |
127.44 |
27.69% |
USD 8,354 |
USD 8,694 |
Radiology accounted for an estimated 38% of 2025 revenue, the largest individual specialty. Its share falls to 31% by 2035 even though absolute revenue grows to USD 4.29 billion. Expansion into cardiology and oncology explains most of the relative shift.
Tempus provides evidence of this migration outside radiology. Its ECG-AF algorithm received FDA 510(k) clearance in 2024, while ECG-LowEF was cleared in 2025. By May 2026, Tempus reported more than 2.5 million patients screened through its cardiology care-gap algorithms and cited a CMS CPT payment benchmark of USD 128 per test.
Market drivers, restraints and strategic opportunities
Quantified market drivers
Regulatory mechanisms for controlled AI modification: Estimated +2.40 percentage-point CAGR impact
FDA policy has reduced one source of commercialization uncertainty for adaptive medical-device software. Its PCCP framework permits a manufacturer to describe specified future changes, the process used to develop and validate those changes and the assessment of their effect on device performance. A modification covered by an authorized PCCP can be implemented without a separate marketing submission for each approved change.
The effect is important for foundation-model architectures because commercial economics depend on repeated model improvement. Credence Research attributes approximately 2.40 percentage points of the base forecast CAGR to shorter update cycles, greater version-control predictability and regulatory investment in lifecycle management. The estimate is an econometric contribution relative to a no-PCCP counterfactual and is not additive on a one-for-one basis with the other driver estimates because interaction effects are included.
Expansion from single-task AI toward foundation-model clinical coverage: Estimated +1.90 percentage-point CAGR impact
The economic model for AI-SaMD is shifting from one algorithm per indication toward architectures capable of supporting multiple clinical tasks. Aidoc’s CARE foundation model has already produced FDA-cleared applications, and its January 2026 comprehensive CT triage clearance brought 11 newly cleared indications together with three existing indications in a single workflow.
Aidoc reported in April 2026 that its technology analyzed more than 60 million patient cases annually and was deployed across nearly 2,000 hospitals at that point. Higher case coverage improves the revenue case for enterprise licensing because hospitals can spread governance, integration and monitoring costs across more conditions.
Cloud-based multimodal model development and enterprise delivery: Estimated +1.55 percentage-point CAGR impact
Foundation models require substantially more compute, storage and model-governance capacity than many earlier task-specific medical algorithms. Cloud infrastructure permits vendors to consolidate those costs across customer accounts and supports model distribution without independent hardware replacement cycles.
GE HealthCare and AWS announced a collaboration to develop healthcare-specific foundation models and generative AI applications. The companies identified medical records, reports and images as multimodal input categories for planned models. Philips has also expanded cloud-based enterprise imaging services and disclosed continued investment in generative AI capabilities within its 2025 annual report.
Quantified restraints and operational bottlenecks
Prospective clinical validation, model drift and liability exposure: Estimated -1.10 percentage-point CAGR drag
Generative systems can produce non-deterministic outputs, which increases validation requirements for software used in diagnosis or treatment decisions. The FDA’s January 2025 lifecycle draft guidance addresses documentation across design, development, implementation and total product lifecycle risk management for AI-enabled device software functions.
The commercial consequence is a longer gap between model capability and monetizable regulated deployment. Foundation-model research can therefore move faster than cleared product revenue. GE HealthCare, for example, has disclosed several foundation-model research programs while separately identifying their research status and intended future application development.
Interoperability, privacy controls and inference economics: Estimated -0.80 percentage-point CAGR drag
Generative medical software must operate inside PACS, RIS, EHR and device environments with institution-specific security requirements. This creates implementation costs beyond the software license. GE HealthCare has identified workflow integration as a material barrier to generative AI adoption in ultrasound reporting, particularly where AI does not fit existing PACS, RIS and EMR infrastructure.
High-resolution imaging models also carry higher inference costs than text-only clinical models. Local data residency rules can prevent vendors from optimizing every deployment through a single shared cloud architecture.
High-return growth opportunities
Multi-condition foundation-model SaMD: The strongest near-term white space is regulated software that moves from one abnormality per algorithm to multi-condition detection and prioritization. The commercial advantage is a lower effective integration cost per indication and a larger addressable procedure base per hospital contract.
Localized multimodal models for Asia-Pacific: Asia-Pacific increases from an estimated 22% of global market value in 2025 to 30% by 2035. Models adapted for local languages, local clinical protocols, sovereign-cloud requirements and population-specific validation can capture premium enterprise contracts that general-purpose English-language clinical systems cannot address efficiently.
Regional and Geographic Market Breakdown
Geographic Forecast
| Region / Country |
2025 Value (USD Mn) |
2035 Value (USD Mn) |
Value CAGR |
2025 Volume (000) |
2035 Volume (000) |
Volume CAGR |
2025 Share |
2035 Share |
| North America |
580.80 |
5,401.50 |
24.98% |
60.0 |
495 |
23.49% |
44.00% |
39.00% |
| United States |
511.10 |
4,591.27 |
24.55% |
52.5 |
420 |
23.11% |
38.72% |
33.15% |
| Canada |
69.70 |
810.22 |
27.80% |
7.5 |
75 |
25.89% |
5.28% |
5.85% |
| Europe |
356.40 |
3,324.00 |
25.02% |
43.0 |
322 |
22.30% |
27.00% |
24.00% |
| Germany |
78.41 |
698.04 |
24.44% |
9.2 |
65 |
21.59% |
5.94% |
5.04% |
| United Kingdom |
71.28 |
631.56 |
24.38% |
8.2 |
59 |
21.82% |
5.40% |
4.56% |
| France |
60.59 |
531.84 |
24.26% |
7.5 |
50 |
20.89% |
4.59% |
3.84% |
| Italy |
39.20 |
365.64 |
25.02% |
4.7 |
34 |
21.88% |
2.97% |
2.64% |
| Spain |
28.51 |
299.16 |
26.50% |
3.4 |
29 |
23.91% |
2.16% |
2.16% |
| Rest of Europe |
78.41 |
797.76 |
26.11% |
10.0 |
85 |
23.86% |
5.94% |
5.76% |
| Asia-Pacific |
290.40 |
4,155.00 |
30.48% |
43.0 |
485 |
27.42% |
22.00% |
30.00% |
| China |
84.22 |
1,246.50 |
30.93% |
13.0 |
145 |
27.27% |
6.38% |
9.00% |
| Japan |
58.08 |
623.25 |
26.78% |
8.0 |
72 |
24.57% |
4.40% |
4.50% |
| India |
49.37 |
997.20 |
35.06% |
8.0 |
130 |
32.16% |
3.74% |
7.20% |
| South Korea |
37.75 |
498.60 |
29.44% |
5.0 |
55 |
27.10% |
2.86% |
3.60% |
| Australia |
23.23 |
290.85 |
28.75% |
4.0 |
34 |
23.86% |
1.76% |
2.10% |
| Rest of APAC |
37.75 |
498.60 |
29.44% |
5.0 |
49 |
25.64% |
2.86% |
3.60% |
| Latin America |
46.20 |
484.75 |
26.50% |
6.0 |
58 |
25.47% |
3.50% |
3.50% |
| Brazil |
22.64 |
218.14 |
25.43% |
2.9 |
26 |
24.53% |
1.72% |
1.58% |
| Mexico |
12.47 |
140.58 |
27.41% |
1.6 |
17 |
26.66% |
0.94% |
1.01% |
| Rest of LATAM |
11.09 |
126.04 |
27.52% |
1.5 |
15 |
25.89% |
0.84% |
0.91% |
| Middle East & Africa |
46.20 |
484.75 |
26.50% |
6.0 |
56 |
25.03% |
3.50% |
3.50% |
| GCC |
21.25 |
237.53 |
27.30% |
2.8 |
28 |
25.89% |
1.61% |
1.72% |
| South Africa |
10.16 |
87.26 |
23.99% |
1.4 |
9 |
20.45% |
0.77% |
0.63% |
| Rest of MEA |
14.78 |
159.97 |
26.89% |
1.8 |
19 |
26.58% |
1.12% |
1.16% |
North America
North America represented an estimated 44% of 2025 revenue, with the United States alone accounting for 38.72% of the global market. The U.S. advantage comes from its combination of FDA regulatory infrastructure, large hospital systems, enterprise imaging software penetration, cloud availability and an established commercial AI vendor base.
FDA’s AI-enabled medical device list provides a formal reference for authorized products and continues to be updated. The agency has also indicated that future updates will improve identification of devices containing LLM and foundation-model functionality. The combination of PCCPs and a growing list of foundation-model-derived devices should support recurring software revenue, although the region’s share decreases to 39% by 2035 because APAC expands faster.
Europe
Europe represented an estimated 27% of 2025 value. Germany, the United Kingdom and France accounted for more than half of European demand. Hospital procurement places significant weight on security, clinical evidence, MDR conformity and data governance, which increases implementation costs but supports higher-value enterprise contracts.
The EU AI Act now follows a phased compliance structure. General-purpose AI model obligations became applicable in August 2025, while the amended timetable places high-risk rules for systems linked to regulated Annex I products on a later implementation date. EUDAMED’s actor registration, UDI/device registration, notified-body certificate and market-surveillance modules became mandatory from May 28, 2026.
Asia-Pacific
Asia-Pacific is forecast to register the highest regional value CAGR at 30.48%, which increases its global share from 22% in 2025 to 30% by 2035. China and India provide the largest incremental revenue contribution, while Japan, South Korea and Australia retain higher normalized software spending per deployment.
The commercial model differs materially from North America. Vendors must adapt clinical evidence packages, language models, hosting architecture and device registration to multiple national systems. This increases initial development cost but creates defensible local product versions. The region therefore supports both multinational vendors and domestic specialists with country-specific medical data access.
Credence Research modeled ranges.
The main bottleneck has moved from basic model development to validated clinical deployment. Access to high-quality labeled medical data remains expensive, but foundation models reduce the amount of task-specific data required for some downstream use cases. GE HealthCare has cited this reduced dependence on extensive labeled data as one rationale for its foundation-model research.
Infrastructure concentration is another exposure. Training and inference depend on a small group of accelerator and cloud suppliers, while hospitals frequently require private-cloud or hybrid configurations. This raises deployment cost and lengthens procurement cycles.
Nearshoring in this market means localized data processing, regional cloud hosting and domestic clinical validation, not relocation of physical manufacturing. Europe, Japan, the Gulf states and parts of APAC increasingly favor architectures that can keep sensitive patient data within approved jurisdictions.
Pricing trends, cost breakdown and unit economics
The market’s average annual price per normalized license-equivalent increases from USD 8,354 in 2025 to USD 9,781 in 2035, equal to a nominal ASP CAGR of approximately 1.59%. The increase is caused primarily by product mix. Basic reporting applications face price compression, while multimodal decision-support applications command higher annual contract values.
Credence Research normalized commercial model. Vendor economics vary materially by scale, customer type and clinical indication.
Unit benchmark callouts
Benchmark 1: Public cloud SaaS annual license-equivalent
2025 modeled ASP: USD 7,342 per year
2035 modeled ASP: USD 8,892 per year
This segment benefits from shared infrastructure and lower customer-specific deployment expense.
Benchmark 2: Private-cloud annual license-equivalent
2025 modeled ASP: USD 8,951 per year
2035 modeled ASP: USD 10,324 per year
Private-cloud deployments carry higher security, validation and environment-management costs.
Benchmark 3: Edge and embedded annual license-equivalent
2025 modeled ASP: USD 9,234 per year
2035 modeled ASP: USD 11,286 per year
Edge deployments retain a premium where latency, data residency or device integration limits centralized cloud inference.
A useful adjacent reimbursement benchmark comes from Tempus. The company reported in May 2026 that CMS had established a CPT reimbursement amount of USD 128 per test for its ECG-based algorithm. This does not represent a generative AI SaMD market ASP, but it shows how algorithmic diagnostic reimbursement can support per-procedure monetization in addition to enterprise subscription pricing.
Research methodology and data triangulation framework
PHASE 1
PRIMARY PROCUREMENT AND COMMERCIAL INPUT FRAME
|
|– Hospital AI procurement architecture
|– Radiology and clinical informatics buying criteria
|– Enterprise software pricing and license normalization
|– Medical-device vendor deployment benchmarks
PHASE 2
ECONOMETRIC CAPACITY AND DEMAND MODELING
|
|– Regulated device deployment base
|– Active license-equivalent conversion
|– Revenue = volume x normalized ASP
|– Specialty, deployment and geographic diffusion curves
|– Bull, base and bear adoption functions
PHASE 3
SECONDARY VALIDATION AND REGULATORY CONSENSUS
|
|– FDA device authorization and PCCP records
|– EU AI Act and EUDAMED implementation data
|– IMDRF SaMD classification framework
|– Audited vendor filings and transaction disclosures
|– Public procurement, company product and deployment evidence
FINAL TRIANGULATED MARKET MODEL
The underlying market definition follows the IMDRF concept of Software as a Medical Device, which establishes software intended for medical purposes that performs those purposes without being part of a hardware medical device.
For this landing-page model, quantitative market estimates use public regulatory, corporate and transaction evidence plus econometric normalization. Proprietary customer interviews, invoice-level procurement checks and primary vendor surveys should be added during full report production before any estimate is represented as directly interview-validated.
Competitive positioning, concentration ratios and vendor market shares
2025 modeled CR4 concentration ratio: 34.80%
2025 modeled HHI: approximately 620
The HHI score indicates a fragmented emerging market. Large imaging OEMs control installed clinical infrastructure, while pure-play AI companies hold valuable regulated algorithms, foundation-model intellectual property and enterprise AI orchestration platforms.
GE HealthCare
Estimated 2025 share: 11.2%
Classification: Tier-1 leader
GE HealthCare combines imaging equipment, enterprise software, AI applications and foundation-model research. The company and AWS announced plans to develop purpose-built healthcare foundation models and generative AI applications for medical diagnostics and clinical workflows. GE HealthCare also developed an MRI foundation-model research program designed to support downstream classification, segmentation, image retrieval and report-generation applications.
Its acquisition strategy has increased control of AI-enabled image analysis and cloud imaging infrastructure. MIM Software, Intelligent Ultrasound’s clinical AI business and Intelerad strengthen different portions of the clinical software stack.
Siemens Healthineers
Estimated 2025 share: 9.1%
Classification: Tier-1 leader
Siemens Healthineers participates through AI-Rad Companion, teamplay-based delivery and research on LLM-supported radiology tools. AI-Rad Companion includes medical-device products and provides automated imaging post-processing, measurements and clinical results for physician review.
Siemens has also disclosed research with large language models for radiological diagnostic assistance and natural-language generation of FHIR queries. Its installed imaging base gives the company a direct distribution path for regulated generative functions once validated.
Philips
Estimated 2025 share: 7.8%
Classification: Tier-1 leader
Philips combines enterprise imaging, cloud infrastructure and AI-based clinical workflow products. The company expanded its AWS-hosted HealthSuite Imaging services into Europe in 2025 after reporting migration of more than 150 sites in North and Latin America. Philips explicitly stated that it was exploring generative AI for radiology reporting within this environment.
Its 2025 annual report states that Philips is expanding generative AI use in technology development and increasingly incorporating generative capabilities in products and services.
Tempus AI
Estimated 2025 share: 6.7%
Classification: Scaled specialist
Tempus combines multimodal clinical data, diagnostic algorithms and precision-medicine applications. The company received FDA clearance for ECG-AF in 2024 and ECG-LowEF in 2025.
Tempus has also disclosed a collaboration with AstraZeneca and Pathos AI to build a multimodal oncology foundation model. Its Q2 2025 materials stated that pretraining was underway with an initial version expected in early 2026. Regulated algorithm deployment and proprietary multimodal data provide a commercial route into future generative decision-support SaMD.
Aidoc
Estimated 2025 share: 5.4%
Classification: Pure-play specialist
Aidoc is one of the clearest examples of foundation-model technology crossing into regulated medical software. CARE supports FDA-cleared applications and is deployed through the company’s aiOS enterprise clinical AI platform.
In January 2026, Aidoc announced FDA clearance for a comprehensive CT triage product combining 11 newly cleared indications with three existing indications. The architecture creates a direct commercial precedent for multi-condition foundation-model SaMD.
Lunit
Estimated 2025 share: 4.6%
Classification: Pure-play specialist
Lunit operates in AI-based cancer detection and treatment-support software. Its acquisition of Volpara added a major breast-health software platform, access to a mammography data repository and a broader U.S. installed base. Lunit stated that Volpara solutions were operating in more than 2,000 U.S. medical sites at the time of the transaction process.
Lunit’s near-term contribution remains weighted toward regulated discriminative AI, but its data base and software distribution position it for autonomous and foundation-model-based cancer applications.
Strategic mergers, acquisitions and financing activity
| Date |
Acquirer / Lead Investor |
Target / Partner Entity |
Deal Value |
Strategic Rationale / Technology Acquired |
| May 22, 2024 |
Lunit |
Volpara Health Technologies |
About USD 193 Mn |
Breast imaging software, mammography data, U.S. screening network and AI cancer diagnostics expansion |
| July 18, 2024 |
GE HealthCare |
Intelligent Ultrasound clinical AI business |
About USD 51 Mn |
Real-time ultrasound image-recognition software and clinical AI development team |
| Feb. 3, 2025 |
Tempus AI |
Ambry Genetics |
USD 600 Mn |
Genetic testing, diagnostic data scale and expansion of multimodal precision-medicine data assets |
| March 18, 2026 |
GE HealthCare |
Intelerad |
USD 2.3 Bn |
Cloud-first enterprise imaging, workflow software, SaaS revenue and AI orchestration infrastructure |
| April 29, 2026 |
Goldman Sachs Alternatives-led financing |
Aidoc |
USD 150 Mn Series E |
CARE foundation-model expansion, additional clinical indications, automated imaging draft-report development and aiOS deployment |
The transaction pattern shows that strategic capital is moving toward proprietary clinical data, enterprise distribution, regulated algorithms and cloud workflow control. Model intellectual property alone does not provide the strongest acquisition case. Buyers place higher value on businesses that combine algorithms with recurring contracts, clinical integration and regulatory approvals.
GE HealthCare’s Intelerad acquisition is the largest transaction in this selected set. The company’s June 2026 SEC filing recorded approximately USD 2.293 billion of cash consideration, including preliminary recognition of USD 1.629 billion in goodwill and USD 845 million in other intangible assets. This valuation structure illustrates the premium attached to recurring software relationships, workflow assets and enterprise imaging distribution.
Persona-specific strategic action directives
Directives for enterprise procurement and sourcing leaders
Procurement teams should separate foundation-model infrastructure cost from application licensing when negotiating multi-year AI-SaMD contracts. Contracts should define minimum clinical performance thresholds, model-version controls, audit access and vendor responsibilities after algorithm updates.
Dual-source procurement is appropriate for high-volume imaging systems where workflow failure would create clinical or operational risk. Buyers should also negotiate algorithm bundles at the health-system level instead of purchasing every indication independently.
Volume rebates should be indexed to annual study volume, active sites or algorithm transactions, depending on the vendor’s cost structure. Contracts tied solely to named users can overprice machine-generated clinical workloads.
Directives for OEM strategy and product engineering leads
R&D budgets should shift toward reusable foundation-model architectures that can support several validated downstream products from a common technical base. Aidoc’s movement from foundation model to multiple cleared conditions offers an early commercial reference for this approach.
Product roadmaps should isolate the regulated clinical function from lower-risk generative workflow components. This permits separate validation cycles and reduces the probability that a non-clinical feature change triggers unnecessary regulatory work.
PCCP strategy should be developed during initial regulatory planning. Update scope, retraining conditions, dataset controls and postmarket monitoring requirements affect future product economics and should not be treated solely as submission documentation.
Directives for private equity and M&A strategy teams
Scaled healthcare SaaS assets with embedded AI can support EV/Revenue multiples above conventional healthcare IT businesses where recurring revenue exceeds 80%, retention is strong and clinical workflow switching costs are high. However, generative AI intellectual property without regulatory clearance or durable clinical distribution warrants a material discount.
For profitable or near-profitable regulated software platforms, an initial screening range of approximately 12x to 20x forward EBITDA is more defensible than revenue-only valuation. Earlier-stage foundation-model businesses require probability-weighted modeling based on clearance timing, contracted health-system access and inference cost.
Preferred acquisition targets include imaging workflow platforms with proprietary datasets, specialty-specific SaMD vendors with multiple FDA or CE-marked indications and regulatory software businesses that can host third-party algorithms.
